EWTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Edgewise Therapeutics Inc (EWTX) is not a strong buy at this time for a beginner investor with a long-term strategy. While the company has potential catalysts in its pipeline, the lack of immediate positive financial performance, mixed analyst sentiment, and absence of strong trading signals suggest holding off on investment until clearer growth indicators emerge.
The stock's MACD is negatively expanding (-0.135), indicating bearish momentum. RSI is neutral at 46.223, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock closed below the pivot level of 29.374, suggesting weak short-term price action. Key support levels are at 27.735 and 26.723, with resistance at 31.013 and 32.025.
Analysts from JPMorgan, Truist, and H.C. Wainwright maintain positive outlooks on the company's EDG-7500 drug, citing its potential in treating HCM and its favorable safety profile. Upcoming Phase 3 data in late 2026 could serve as a significant catalyst.
Stifel raised concerns about safety issues with EDG-7500, including atrial fibrillation, and noted that meaningful data won't be available until Phase 3 trials, which are years away. The stock also lacks immediate catalysts, and the broader market sentiment is neutral.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$40.67 million, albeit with a 19.15% YoY improvement. EPS improved slightly to -0.39 (up 8.33% YoY), but the company remains unprofitable.
Analyst ratings are mixed. JPMorgan and Truist are bullish, with JPMorgan assigning an Overweight rating and Truist maintaining a Buy rating with a $46 price target. However, Stifel is cautious with a Hold rating, citing unresolved safety concerns and lack of near-term catalysts.
